Regulatory Context for Oncology

Oncology sits at the intersection of federal drug law, state medical licensing, institutional accreditation, and payer policy — a layered framework that shapes how cancer diagnostics, treatments, and clinical research operate across the United States. Understanding this regulatory structure clarifies why certain therapies require specific approvals, why off-label prescribing carries distinct legal weight, and why a drug approved for one cancer type cannot automatically be marketed for another. This page maps the governing agencies, the federal-state authority split, the trajectory of regulatory change, and the gaps that remain unresolved.

Where gaps in authority exist

Regulatory coverage in oncology is uneven across three identifiable domains: companion diagnostics, off-label use, and artificial intelligence–assisted tools.

Companion diagnostics — tests that identify whether a patient's tumor expresses a biomarker targeted by a specific drug — are regulated by the FDA under 21 CFR Part 820 as in vitro diagnostic devices. However, laboratory-developed tests (LDTs) created and used within a single certified laboratory have historically operated under enforcement discretion rather than premarket review. The FDA's 2024 final rule on laboratory-developed tests moves to phase out that discretion over a four-year period, but a gap persists during the transition. Oncology pages covering molecular profiling and biomarkers reflect how consequential this gap is for treatment selection.

Off-label prescribing is legal under federal law but sits outside FDA-approved labeling. The FDA does not regulate the practice of medicine directly; prescribers may use approved drugs for unapproved indications based on clinical evidence. Medicare coverage for off-label oncology drugs is governed by Medicare Benefit Policy Manual, Chapter 15, §50.4.5, which permits coverage when the use is supported by one of four recognized drug compendia — AHFS Drug Information, Drugs@FDA, Micromedex, or Clinical Pharmacology.

AI-assisted diagnostic and treatment-planning tools in oncology are regulated as Software as a Medical Device (SaMD) under FDA's Digital Health Center of Excellence guidance. Premarket pathways (510(k), De Novo, or PMA) apply depending on intended use and risk level, but post-market algorithmic updates can occur without re-review under current policy — a recognized oversight gap.

How the regulatory landscape has shifted

Three structural shifts have reshaped oncology regulation since 2012.

1. Breakthrough Therapy Designation (BTD): Established under the FDA Safety and Innovation Act of 2012 (Public Law 112-144), BTD accelerates development of drugs showing preliminary evidence of substantial improvement over existing therapy. As of FDA reporting, oncology accounts for a majority of BTD grants, compressing the median review timeline.

2. Accelerated Approval reform: The Omnibus Act of 2022 (Public Law 117-328) gave FDA explicit authority to require post-approval confirmatory trials to run concurrently with accelerated approval marketing, rather than beginning after approval. This directly addressed the problem of oncology drugs remaining on the market for years without confirmatory evidence.

3. Real-World Evidence (RWE) frameworks: The 21st Century Cures Act of 2016 (Public Law 114-255) directed FDA to develop a framework for using real-world data to support drug approvals and labeling changes. FDA's Real-World Evidence Program has since issued multiple guidance documents specific to oncology endpoints.

Governing sources of authority

Oncology is governed by overlapping federal statutes, agency regulations, and professional accreditation standards:

• FDA (Food and Drug Administration): Drug approval under 21 U.S.C. §355 (the Federal Food, Drug, and Cosmetic Act); biologic approval under 42 U.S.C. §262 (the Public Health Service Act); device regulation under 21 CFR Parts 800–898.
• CMS (Centers for Medicare & Medicaid Services): Coverage determinations under the Medicare program, including National Coverage Determinations (NCDs) for chemotherapy, radiation oncology, and cancer screening. CMS's coverage determination database is the authoritative public record.
• CLIA (Clinical Laboratory Improvement Amendments, 42 U.S.C. §263a): Sets proficiency, personnel, and quality standards for any laboratory — including hospital pathology labs — that processes oncology diagnostic specimens.
• NCI (National Cancer Institute): Funds and oversees cooperative group clinical trials through the National Clinical Trials Network (NCTN). NCI designation for cancer centers carries programmatic and funding criteria distinct from CMS accreditation standards.
• CoC (Commission on Cancer): An accreditation program of the American College of Surgeons that sets 34 evidence-based standards for cancer program quality, multidisciplinary care, and survivorship planning. CoC accreditation is voluntary but affects payer relationships and institutional reputation.

Clinical trials — a central mechanism in oncology care — are further governed by FDA regulations at 21 CFR Parts 50, 56, and 312 (Investigational New Drug applications), along with the Common Rule (45 CFR Part 46) administered by the Office for Human Research Protections (OHRP). Patients considering clinical trials navigate requirements set by both frameworks simultaneously.

Federal vs state authority structure

Federal law sets the floor for oncology drug approval, clinical trial conduct, and laboratory standards. State law governs the practice of medicine, professional licensing, and the scope of what each licensed provider may do.

This division creates 4 distinct friction points:

1. Prescribing authority: Physician licensing is state-controlled. A drug approved federally may still only be prescribed by a provider licensed in the relevant state, under that state's Medical Practice Act.
2. Telemedicine oncology consultations: When a patient in one state consults a specialist licensed in another, the applicable standard of care, scope rules, and prescribing authority are determined by the patient's state of physical location — not the physician's state of licensure.
3. State drug coverage mandates: 43 states have enacted laws requiring health insurers to cover off-label cancer drug use when supported by recognized compendia, per the National Conference of State Legislatures' cancer treatment mandates tracking. Federal law does not require this for all plan types, creating coverage variation by insurance product.
4. Certificate of Need (CON) laws: 35 states maintain CON programs that regulate whether new radiation therapy facilities, PET scanners, or other capital-intensive oncology infrastructure can be built in a given market. CON requirements directly affect geographic access to cancer care.

The main oncology reference provides additional context for understanding how these regulatory layers intersect with clinical practice, diagnosis pathways, and treatment decision-making across cancer types including breast cancer, lung cancer, and leukemia.

References

• FDA — Federal Food, Drug, and Cosmetic Act (21 U.S.C. §355)
• FDA — Breakthrough Therapy Designation
• FDA — Real-World Evidence Program
• FDA — Digital Health Center of Excellence
• Federal Register — Final Rule on Laboratory-Developed Tests (2024)
• CMS — Medicare Coverage Database
• CMS — Medicare Benefit Policy Manual, Chapter 15
• OHRP — The Common Rule (45 CFR Part 46)
• NCSL — Cancer Treatment Coverage Mandates
• NCI — National Clinical Trials Network (NCTN)
• American College of Surgeons — Commission on Cancer
• 21st Century Cures Act (Public Law 114-255)

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)